Current status of diagnosis for synchronous endometrial and ovarian carcinomas by molecular biological approach

The diagnosis of synchronous carcinomas is difficult in all types of cancer. However, in gynecological cancers, synchronous endometrial and ovarian carcinomas are rarely seen and are more difficult to diagnose because the uterus and ovaries are adjacent organs. Although classical pathological criteria have been used for diagnosis, molecular biological methods are increasingly being used to refine diagnostic decisions. Through genomic analyses, such as next-generation sequencing and targeted and exome sequencing, many cases that have been diagnosed and treated as primary synchronous carcinomas have been determined to actually be metastatic carcinomas. It is necessary to establish new diagnostic criteria by incorporating molecular biological methods with conventional pathological diagnosis.

Synchronous endometrial and ovarian carcinoma; Molecular biological approach; Genomic analyses; Next-generation sequencing; Targeted and exome sequencing

[1] Khalid N, Ullah F, Zafar H, Anwer AW, Abbas T, Shakeel O, et al. Synchronous Primary Endometrial and Ovarian Cancers: Trends and Outcomes of the Rare Disease at a South Asian Tertiary Care Cancer Center. Cureus. 2020; 12: e9163.

[2] Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously Detected Endometrial and Ovarian Carcinomas—a Prospective Clinicopathologic Study of 74 Cases: a Gynecologic Oncology Group Study. Gynecologic Oncology. 2001; 83: 355–362.

[3] Lim YK, Padma R, Foo L, Chia YN, Yam P, Chia J, et al. Survival outcome of women with synchronous cancers of endometrium and ovary: a 10 year retrospective cohort study. Journal of Gynecologic Oncology. 2011; 22: 239–243.

[4] Heitz F, Amant F, Fotopoulou C, Battista MJ, Wimberger P, Traut A, et al. Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study. International Journal of Gynecologic Cancer. 2014; 24: 54–60.

[5] Williams MG, Bandera EV, Demissie K, Rodríguez-Rodríguez L. Synchronous Primary Ovarian and Endometrial Cancers. Obstet- rics & Gynecology. 2009; 113: 783–789.

[6] Izadi-Mood N, Sadidi H, Sarmadi S, Yarandi F, Amini- Moghaddam S, Esfahani F, et al. Comparison of clinicopathologic variables in coexistence cancers of the endometrium and ovary: a review of 55 cases in an academic center in Iran. Journal of Research in Medical Sciences. 2015; 20: 727–732.

[7] Bese T, Sal V, Kahramanoglu I, Tokgozoglu N, Demirkiran F, Turan H, et al. Synchronous Primary Cancers of the Endometrium and Ovary with the same Histopathologic Type Versus Endometrial Cancer with Ovarian Metastasis. International Journal of Gynecological Cancer. 2016; 26: 394–406.

[8] Narin MA, Karalok A, Basaran D, Ureyen I, Turkmen O, Turan T, et al. Does synchronous endometrioid endometrial cancer have any prognostic effect on Stage i endometrioid ovarian cancer? European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016; 200: 113–116.

[9] Zhan X, Li L, Wu M, Lang J. The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas. Archives of Gynecology and Obstetrics. 2019; 300: 1045–1052.

[10] Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Human Pathology. 1985; 16: 28–34.

[11] Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology Third Series, Fasc 23. Armed Forces Institute of Pathology: Washington, DC. 1996.

[12] World Health Organization. Female Genital Tumours. WHO Classification of Tumours. 5th edn. 2020.

[13] Chao A, Wu RC, Jung SM, Lee YS, Chen SJ, Lu YL, et al. Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology. Gynecologic Oncology. 2016; 143: 60–67.

[14] Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, et al. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. Journal of the National Cancer Institute. 2016; 108: djv428.

[15] Schultheis AM, Ng CKY, De Filippo MR, Piscuoglio S, Macedo GS, Gatius S, et al. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. Journal of the National Cancer Institute. 2015; 108: djv427.

[16] Hájková N, Tichá I, Hojný J, Němejcová K, Bártů M, Michálková R, et al. Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases. Oncology Letters. 2019; 17: 2207–2214.

[17] Ishikawa M, Nakayama K, Nakamura K, Ono R, Yamashita H, Ishibashi T, et al. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma. Human Pathology. 2019; 85: 92–100.

[18] Reijnen C, Küsters-Vandevelde HVN, Ligtenberg MJL, Bulten J, Oosterwegel M, Snijders MPLM, et al. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome. International Journal of Cancer. 2020; 147: 478–489.

[19] Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt A, Bellini E, et al. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing–a case report. BMC Cancer. 2017; 17: 66.

[20] Watson P, Lynch HT. Cancer risk in mismatch repair gene mutation carriers. Familial Cancer. 2001; 1: 57–60.

[21] Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broad- dus RJ, et al. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers from GOG210: an NRG On- cology and Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2015; 33: 4301–4308.

[22] Niskakoski A, Pasanen A, Porkka N, Eldfors S, Lassus H, Renkonen-Sinisalo L, et al. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas. Gynecologic Oncology. 2018; 150: 92–98.

[23] Liu Y, Li J, Jin H, Lu Y, Lu X. Clinicopathological characteristics of patients with synchronous primary endometrial and ovarian cancers: a review of 43 cases. Oncology Letters. 2013; 5: 267–270.

[24] Iacobelli V, Zannoni GF, Gui B, Fagotti A, Scambia G, Fanfani F. Molecular and biological profile may discriminate between synchronous or metachronous endometrial and ovarian cancer. International Journal of Gynecologic Cancer. 2020; 30: 1071–1076.

[25] Moukarzel LA, Da Cruz Paula A, Ferrando L, Hoang T, Sebas- tiao APM, Pareja F, et al. Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syn- dromes. Modern Pathology. 2021; 34: 994–1007.

[26] Kobayashi Y, Nakamura K, Nomura H, Banno K, Irie H, Adachi M, et al. Clinicopathologic Analysis with Immunohistochemistry for DNA Mismatch Repair Protein Expression in Synchronous Primary Endometrial and Ovarian Cancers. International Journal of Gynecological Cancer. 2015; 25: 440–446.

[27] Yoshihara K, Enomoto T, Aoki D, Watanabe Y, Kigawa J, Takeshima N, et al. Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHAR- LOTTE study. Cancer Science. 2020; 111: 3350–3358.

[28] Manchana T, Phowthongkum P, Teerapakpinyo C. Germline mu- tations in Thai patients with nonmucinous epithelial ovarian cancer. World Journal of Clinical Oncology. 2019; 10: 358–368.